New research suggests a critical difference in how Alzheimer’s disease manifests in women versus men. A postmortem study published in JAMA Neurology reveals that women consistently exhibit a greater burden of amyloid plaques in the brain – a hallmark of Alzheimer’s – than their male counterparts. This difference isn’t uniform, yet, and appears to be significantly shaped by factors like race, genetic ancestry, and the presence of the APOE ε4 gene.
Understanding these nuances is crucial as scientists race to develop effective treatments for Alzheimer’s disease, a devastating neurodegenerative condition affecting millions worldwide. Currently, over 6 million Americans are living with Alzheimer’s, and that number is projected to rise dramatically as the population ages, according to the National Institute on Aging.
The study, led by researchers analyzing data from the Biobank for Aging Studies, examined the brains of 2,268 individuals who underwent autopsies between April 2004 and March 2025. Researchers focused on neuritic plaque burden, using the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) scoring system, and correlated this with cognitive impairment as measured by the Clinical Dementia Rating–Sum of Boxes. The findings indicate that women had nearly double the odds of having a higher neuritic plaque burden compared to men, even after accounting for other variables.
Sex, Genetics, and Racial Differences in Amyloid Buildup
The research team found that women demonstrated significantly higher neuritic plaque burden compared with men (an unadjusted odds ratio of 1.97), which remained significant even after statistical adjustments (odds ratio of 1.65). This suggests the difference isn’t simply due to lifestyle factors or other confounding variables. The presence of the APOE ε4 gene, a known genetic risk factor for Alzheimer’s, amplified this difference. Individuals carrying the APOE ε4 gene had approximately four times higher odds of greater neuritic plaque burden, regardless of sex.
Interestingly, the study also highlighted the role of race and ancestry. Black participants and those with African ancestry generally showed lower plaque burden than White participants, particularly among those *without* the APOE ε4 gene. However, this protective effect disappeared among APOE ε4 carriers, suggesting the gene overrides any ancestral differences in plaque accumulation. Researchers identified significant interactions between sex, APOE ε4 status, race, and ancestry, indicating a complex interplay of factors influencing Alzheimer’s pathology.
Beyond Amyloid: Tau Pathology and Cognitive Decline
The study’s findings extend beyond amyloid plaques. Researchers also observed that women with moderate or frequent amyloid plaques were more likely than men to exhibit advanced stages of neurofibrillary tangles – another key pathological feature of Alzheimer’s, composed of a protein called tau. This suggests that in women, amyloid buildup may be more readily linked to the spread of tau pathology, potentially accelerating cognitive decline. The Alzheimer’s Association explains that the relationship between amyloid and tau is complex, but both contribute to the disease process.
The participants in the study had a median age of 74.8 years, with 51% being men, 35% Black, and 65% White. Notably, women in the study were generally older and had a higher prevalence of cognitive impairment and hypertension, whereas men reported higher rates of smoking and heavy alcohol use. These pre-existing health conditions could potentially influence the development and progression of Alzheimer’s, though the study adjusted for these factors.
Implications for Alzheimer’s Research and Treatment
The researchers emphasize that these findings underscore the need to move beyond a “one-size-fits-all” approach to Alzheimer’s research and treatment. “These findings highlight the importance of incorporating sex, race, and ancestry into biomarker thresholds, risk stratification, and the design of preventive or disease-modifying trials for Alzheimer disease,” the study authors concluded.
Currently, diagnostic criteria and clinical trials often fail to account for these biological differences, potentially leading to inaccurate diagnoses and ineffective treatments. For example, current PET scans used to detect amyloid plaques may need to be recalibrated based on sex and ethnicity to provide more accurate assessments. Similarly, clinical trials should actively recruit diverse populations and analyze data separately for different subgroups to identify treatments that are most effective for specific groups.
The study’s limitations, as acknowledged by the researchers, include its cross-sectional design, which prevents conclusions about cause and effect. The autopsy-based nature of the study also means it doesn’t capture the full spectrum of Alzheimer’s progression. The researchers note that differences in survival rates between men and women could introduce some residual confounding factors.
Looking ahead, researchers are planning further studies to investigate the underlying biological mechanisms driving these sex- and race-related differences in Alzheimer’s pathology. The National Institute on Aging is currently funding several large-scale longitudinal studies aimed at tracking cognitive decline and identifying biomarkers for early detection. The Alzheimer’s Association provides resources and support for individuals and families affected by the disease, as well as updates on the latest research findings.
This research represents a crucial step toward a more personalized and effective approach to combating Alzheimer’s disease. By acknowledging and addressing the biological diversity of this complex condition, we can pave the way for more targeted prevention strategies and treatments that benefit all those at risk.
Do you have thoughts on this new research? Share your comments below, and please consider sharing this article with your network to raise awareness about the importance of personalized Alzheimer’s research.
